Bio-rad Laboratories, Inc. (BIO)

$276.47

-1.74

(-0.63%)▲

Live

Insights on Bio-rad Laboratories, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 632.12M → 681.18M (in $), with an average increase of 7.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -1.16B → 349.70M (in $), with an average increase of 631.7% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 42.7% return, outperforming this stock by 79.1%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 70.6% return, outperforming this stock by 127.2%

Performance

  • $272.45
    $277.88
    $276.47
    downward going graph

    1.45%

    Downside

    Day's Volatility :1.95%

    Upside

    0.51%

    downward going graph
  • $261.59
    $473.50
    $276.47
    downward going graph

    5.38%

    Downside

    52 Weeks Volatility :44.75%

    Upside

    41.61%

    downward going graph

Returns

PeriodBio-rad Laboratories, Inc.Sector (Health Care)S&P500
3 Months
-12.04%
1.7%
3.6%
6 Months
-4.09%
11.3%
21.1%
1 Year
-36.38%
5.4%
24.6%
3 Years
-57.09%
13.9%
21.3%

Highlights

Market Capitalization
8.1B
Book Value
$306.51
Earnings Per Share (EPS)
-21.81
PEG Ratio
1.19
Wall Street Target Price
409.8
Profit Margin
-23.86%
Operating Margin TTM
14.24%
Return On Assets TTM
1.77%
Return On Equity TTM
-6.94%
Revenue TTM
2.7B
Revenue Per Share TTM
91.45
Quarterly Revenue Growth YOY
-6.7%
Gross Profit TTM
1.6B
EBITDA
511.6M
Diluted Eps TTM
-21.81
Quarterly Earnings Growth YOY
-0.56
EPS Estimate Current Year
10.56
EPS Estimate Next Year
12.0
EPS Estimate Current Quarter
2.82
EPS Estimate Next Quarter
3.28

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Bio-rad Laboratories, Inc.(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
10
Hold
2
2
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 48.23%

Current $276.47
Target $409.80

Company Financials

FY18Y/Y Change
Revenue
2.3B
↑ 6.02%
Net Income
361.0M
↑ 214.62%
Net Profit Margin
15.76%
↑ 10.45%
FY19Y/Y Change
Revenue
2.3B
↑ 0.94%
Net Income
1.8B
↑ 387.17%
Net Profit Margin
76.08%
↑ 60.32%
FY20Y/Y Change
Revenue
2.5B
↑ 10.12%
Net Income
3.8B
↑ 116.88%
Net Profit Margin
149.83%
↑ 73.75%
FY21Y/Y Change
Revenue
2.9B
↑ 14.81%
Net Income
4.3B
↑ 11.54%
Net Profit Margin
145.57%
↓ 4.26%
FY22Y/Y Change
Revenue
2.8B
↓ 4.12%
Net Income
-3.6B
↓ 185.27%
Net Profit Margin
-129.45%
↓ 275.02%
FY23Y/Y Change
Revenue
2.7B
↓ 4.67%
Net Income
-637.3M
↓ 82.43%
Net Profit Margin
-23.86%
↑ 105.59%
Q3 FY22Q/Q Change
Revenue
680.8M
↓ 1.49%
Net Income
-164.2M
↓ 82.29%
Net Profit Margin
-24.12%
↑ 110.04%
Q4 FY22Q/Q Change
Revenue
730.3M
↑ 7.27%
Net Income
833.5M
↓ 607.51%
Net Profit Margin
114.13%
↑ 138.25%
Q1 FY23Q/Q Change
Revenue
676.8M
↓ 7.32%
Net Income
69.0M
↓ 91.73%
Net Profit Margin
10.19%
↓ 103.94%
Q2 FY23Q/Q Change
Revenue
681.1M
↑ 0.63%
Net Income
-1.2B
↓ 1785.35%
Net Profit Margin
-170.64%
↓ 180.83%
Q3 FY23Q/Q Change
Revenue
632.1M
↓ 7.19%
Net Income
106.3M
↓ 109.14%
Net Profit Margin
16.81%
↑ 187.45%
Q4 FY23Q/Q Change
Revenue
681.2M
↑ 7.76%
Net Income
349.7M
↑ 229.12%
Net Profit Margin
51.34%
↑ 34.53%
FY18Y/Y Change
Total Assets
5.6B
↑ 31.17%
Total Liabilities
1.6B
↑ 18.35%
FY19Y/Y Change
Total Assets
8.0B
↑ 42.92%
Total Liabilities
2.3B
↑ 41.94%
FY20Y/Y Change
Total Assets
13.0B
↑ 61.98%
Total Liabilities
3.1B
↑ 37.22%
FY21Y/Y Change
Total Assets
17.8B
↑ 37.03%
Total Liabilities
4.1B
↑ 32.85%
FY22Y/Y Change
Total Assets
13.5B
↓ 24.04%
Total Liabilities
3.9B
↓ 5.41%
FY23Y/Y Change
Total Assets
12.3B
↓ 8.91%
Total Liabilities
3.6B
↓ 8.45%
Q3 FY22Q/Q Change
Total Assets
12.1B
↓ 4.92%
Total Liabilities
3.6B
↓ 4.11%
Q4 FY22Q/Q Change
Total Assets
13.5B
↑ 11.97%
Total Liabilities
3.9B
↑ 7.81%
Q1 FY23Q/Q Change
Total Assets
13.7B
↑ 1.23%
Total Liabilities
3.9B
↑ 0.44%
Q2 FY23Q/Q Change
Total Assets
12.0B
↓ 12.36%
Total Liabilities
3.5B
↓ 9.54%
Q3 FY23Q/Q Change
Total Assets
11.9B
↓ 0.69%
Total Liabilities
3.5B
↓ 1.46%
Q4 FY23Q/Q Change
Total Assets
12.3B
↑ 3.39%
Total Liabilities
3.6B
↑ 2.25%
FY18Y/Y Change
Operating Cash Flow
285.5M
↑ 174.82%
Investing Cash Flow
-187.0M
↑ 6.5%
Financing Cash Flow
-48.7M
↓ 14375.66%
FY19Y/Y Change
Operating Cash Flow
457.9M
↑ 60.39%
Investing Cash Flow
-208.9M
↑ 11.72%
Financing Cash Flow
-22.8M
↓ 53.25%
FY20Y/Y Change
Operating Cash Flow
575.3M
↑ 25.65%
Investing Cash Flow
-60.3M
↓ 71.16%
Financing Cash Flow
-523.0M
↑ 2198.27%
FY21Y/Y Change
Operating Cash Flow
656.5M
↑ 14.11%
Investing Cash Flow
-784.4M
↑ 1201.97%
Financing Cash Flow
-55.4M
↓ 89.4%
FY22Y/Y Change
Operating Cash Flow
194.4M
↓ 70.38%
Investing Cash Flow
-1.2B
↑ 53.94%
Financing Cash Flow
973.6M
↓ 1856.44%
Q3 FY22Q/Q Change
Operating Cash Flow
7.5M
↓ 85.03%
Investing Cash Flow
-84.9M
↓ 39.96%
Financing Cash Flow
-8.8M
↓ 92.77%
Q4 FY22Q/Q Change
Operating Cash Flow
90.4M
↑ 1103.35%
Investing Cash Flow
-69.3M
↓ 18.36%
Financing Cash Flow
-86.6M
↑ 887.45%
Q1 FY23Q/Q Change
Operating Cash Flow
98.1M
↑ 8.51%
Investing Cash Flow
-70.5M
↑ 1.67%
Financing Cash Flow
4.3M
↓ 104.97%
Q2 FY23Q/Q Change
Operating Cash Flow
98.1M
↓ 0.05%
Investing Cash Flow
28.0M
↓ 139.71%
Financing Cash Flow
-202.7M
↓ 4804.99%
Q3 FY23Q/Q Change
Operating Cash Flow
97.7M
↓ 0.36%
Investing Cash Flow
-52.0M
↓ 285.78%
Financing Cash Flow
-26.6M
↓ 86.88%

Technicals Summary

Sell

Neutral

Buy

Bio-rad Laboratories, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bio-rad Laboratories, Inc.
Bio-rad Laboratories, Inc.
-18.44%
-4.09%
-36.38%
-57.09%
-6.92%
Abbott Laboratories
Abbott Laboratories
-2.84%
14.24%
-2.8%
-12.8%
36.85%
Stryker Corporation
Stryker Corporation
-4.04%
30.03%
12.47%
26.98%
79.97%
Dexcom, Inc.
Dexcom, Inc.
-1.59%
63.45%
11.22%
31.69%
366.88%
Boston Scientific Corp.
Boston Scientific Corp.
8.35%
45.85%
42.65%
72.49%
97.43%
Medtronic Plc
Medtronic Plc
-3.44%
12.58%
-10.38%
-38.23%
-7.46%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bio-rad Laboratories, Inc.
Bio-rad Laboratories, Inc.
31.53
NA
1.19
10.56
-0.07
0.02
NA
306.51
Abbott Laboratories
Abbott Laboratories
33.52
33.52
5.99
4.31
0.15
0.06
0.02
22.26
Stryker Corporation
Stryker Corporation
40.64
40.64
2.92
11.85
0.18
0.07
0.01
48.92
Dexcom, Inc.
Dexcom, Inc.
102.89
102.89
2.53
1.76
0.26
0.06
NA
5.37
Boston Scientific Corp.
Boston Scientific Corp.
64.48
64.48
1.8
2.25
0.09
0.04
NA
13.16
Medtronic Plc
Medtronic Plc
25.81
25.81
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bio-rad Laboratories, Inc.
Bio-rad Laboratories, Inc.
Buy
$8.1B
-6.92%
31.53
-23.86%
Abbott Laboratories
Abbott Laboratories
Buy
$186.7B
36.85%
33.52
13.96%
Stryker Corporation
Stryker Corporation
Buy
$127.4B
79.97%
40.64
15.44%
Dexcom, Inc.
Dexcom, Inc.
Buy
$54.6B
366.88%
102.89
14.95%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$101.4B
97.43%
64.48
11.18%
Medtronic Plc
Medtronic Plc
Buy
$107.9B
-7.46%
25.81
13.0%

Institutional Holdings

  • Vanguard Group Inc

    8.38%

  • BlackRock Inc

    5.14%

  • Veritas Asset Management LLP

    3.80%

  • State Street Corporation

    3.07%

  • UBS Asset Mgmt Americas Inc

    1.76%

  • Geode Capital Management, LLC

    1.61%

Company Information

bio-rad laboratories (nyse: bio and biob) offers a broad range of innovative tools and services to the life science research and clinical diagnostics markets. founded in 1952, bio-rad has a global team of more than 7,600 employees and serves more than 100,000 research and industry customers worldwide through the company's global network of operations. throughout its existence, bio-rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, medical diagnostics, and more. based in hercules, ca, bio-rad has operations worldwide.

Organization
Bio-rad Laboratories, Inc.
Employees
8030
CEO
Mr. Norman D. Schwartz
Industry
Health Technology

Discover More

FAQs